D-0750-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-812-03
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0751-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-822-02
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0752-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-810-01
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0753-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-711-02
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0754-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.NDC 71170-712-03
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0755-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-721-01
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0756-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-722-02
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0757-2026
Class IIFDA report: Aug 19, 2026Recalling firm: Apollo Care, LLC
SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-724-04.
Reason for recall
Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0471-2026
Class IIFDA report: Apr 22, 2026Recalling firm: PAYLESS COMPOUNDERS, LLC
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0379-2026
Class IIFDA report: Mar 11, 2026Recalling firm: Harbin Jixianglong Biotech Co., Ltd.
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
Reason for recall
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0380-2026
Class IIFDA report: Mar 11, 2026Recalling firm: Harbin Jixianglong Biotech Co., Ltd.
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.
Reason for recall
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0392-2026
Class IIFDA report: Mar 11, 2026Recalling firm: New Life Pharma LLC
Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-07.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0393-2026
Class IIFDA report: Mar 11, 2026Recalling firm: New Life Pharma LLC
Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0244-2026
Class IIFDA report: Jan 7, 2026Recalling firm: Novo Nordisk Inc.
Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14
Reason for recall
Presence of Particulate Matter: Hair was found in a prefilled syringe
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0245-2026
Class IIFDA report: Jan 7, 2026Recalling firm: Novo Nordisk Inc.
Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14
Reason for recall
Presence of Particulate Matter: Hair was found in a prefilled syringe
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0114-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0115-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0116-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0117-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0118-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0119-2026
Class IIFDA report: Nov 5, 2025Recalling firm: ProRx LLC
Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0083-2026
Class IIFDA report: Oct 15, 2025Recalling firm: GenoGenix LLC
Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0091-2026
Class IIFDA report: Oct 15, 2025Recalling firm: GenoGenix LLC
Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Synergy Wellness, 20 mg, 10mL vial lyophilized.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0606-2025
Class IIFDA report: Sep 10, 2025Recalling firm: Boothwyn Pharmacy LLC
Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
Reason for recall
Subpotent Drug
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0608-2025
Class IIFDA report: Sep 10, 2025Recalling firm: Boothwyn Pharmacy LLC
Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
Reason for recall
Subpotent Drug
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0609-2025
Class IIFDA report: Sep 10, 2025Recalling firm: Boothwyn Pharmacy LLC
Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy
Reason for recall
Subpotent Drug
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0553-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0561-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0562-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0563-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0564-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0565-2025
Class IIFDA report: Aug 13, 2025Recalling firm: AEQUITA PHARMACY
Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034.
Reason for recall
Lack of Processing Controls.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0479-2025
Class IIFDA report: Jul 2, 2025Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0480-2025
Class IIFDA report: Jul 2, 2025Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0481-2025
Class IIFDA report: Jul 2, 2025Recalling firm: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0393-2025
Class IIFDA report: May 7, 2025Recalling firm: Cardinal Health Inc.
Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14.
Reason for recall
Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0650-2024
Class IIFDA report: Sep 11, 2024Recalling firm: ProRx LLC
Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0652-2024
Class IIFDA report: Sep 11, 2024Recalling firm: ProRx LLC
SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0653-2024
Class IIFDA report: Sep 11, 2024Recalling firm: ProRx LLC
SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0654-2024
Class IIFDA report: Sep 11, 2024Recalling firm: ProRx LLC
Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1105-2023
Class IIFDA report: Aug 30, 2023Recalling firm: TMC Acquisitions LLC dba Tailor Made Compounding
Semaglutide/Cyanocobalamin 2mg/0.4mg/mL, 1mLvials, Tailor Made Compounding.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0538-2023
Class IIFDA report: Apr 26, 2023Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder
C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402
Reason for recall
Lack of assurance of sterility.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0236-2023
Class IIFDA report: Feb 1, 2023Recalling firm: Pharmacy Innovations
SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 5.4MG/ML (0.5ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
Reason for recall
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0053-2023
Class IIFDA report: Nov 9, 2022Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder
SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402
Reason for recall
Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1519-2022
Class IIFDA report: Sep 21, 2022Recalling firm: Carolina Infusion
Semaglutide/Cyanocobalamin 5/2 MG/ML Injectable, 0.2 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1520-2022
Class IIFDA report: Sep 21, 2022Recalling firm: Carolina Infusion
Semaglutide/Cyanocobalamin 10/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1521-2022
Class IIFDA report: Sep 21, 2022Recalling firm: Carolina Infusion
Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936.
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1224-2022
Class IIFDA report: Jul 20, 2022Recalling firm: TMC Acquisition LLC dba Tailor Made Compounding
Semaglutide/Cyanocobalamin 2mg/0.4mg/ml, 1mL-vial, Refrigerate, Tailor Made Compounding
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-1225-2022
Class IIFDA report: Jul 20, 2022Recalling firm: TMC Acquisition LLC dba Tailor Made Compounding
Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate, Tailor Made Compounding
Reason for recall
Lack of Assurance of Sterility
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0536-2021
Class IIFDA report: Jun 2, 2021Recalling firm: Cardinal Health Inc.
Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark
Reason for recall
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026
D-0617-2021
Class IIFDA report: Apr 21, 2021Recalling firm: Novo Nordisk Inc
OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit)
Reason for recall
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026